IRVINE, California, and AMSTERDAM, August
5, 2010 /PRNewswire/ — Agendia, a world leader in molecular
cancer diagnostics, today announced the inauguration of a new
state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia’s
offices and laboratory were located in Huntington Beach, CA. The new laboratory
will further increase capacity to support Agendia’s strong
commercial expansion in the U.S. market, as well as the use of
multiple Agendia tests in clinical research. MammaPrint, the
company’s lead product and the only FDA-cleared breast cancer
recurrence test, is reimbursed by an increasing number of payers,
covering some 100 million lives today.
(Photo: http://www.newscom.com/cgi-bin/prnh/20100805/402822-a )
(Photo: http://www.newscom.com/cgi-bin/prnh/20100805/402822-b )
In addition, MammaPrint plays a central role in the recently
initiated I-SPY 2 trial, which is a revolutionary breast cancer
trial and an initiative of the Biomarkers Consortium, a unique
public-private partnership that includes the Food and Drug
Administration, the National Institutes of Health, and major
pharmaceutical companies, led by the Foundation for the National
Institutes of Health. The I-SPY 2 trial, which will enroll patients
at 20 leading U.S. cancer research centers, will also rely on
Agendia’s TargetPrint to provide objective, quantitative
information about the expression of the specific tumor-related
proteins, E
‘/>”/>
